Xience V/Promus, Xience Prime, Promus Element, ABSORB drug-eluting coronary artery stents (DES):-Identified Guidant Medical Devices as partner to develop everolimus-eluting stents-Xience V/Promus has taken ~60% of world-wide DES market -To date, Novartis continues to receive significant profits from royalties and milestone payments-Xience Prime, next generation Xience V, has received CE Mark and contributing to royalty stream-Promus Element (Boston Scientific) has received CE Mark and contributing to royalty stream-ABSORB, the first completely biodegradable everolimus-eluting stent, granted CE Mark 1/2011Licensing of SAR 943 to Atrium Medical Devices and Elixir Medical Devices:-SAR 943 is analog of everolimus without clinical and safety data and GMP material unavailable.-Licensed SAR 943 in ‘total’: Licensee assumes responsibility of GMP batch sysnthesis, preclinical safety studies and -limited clinical safety program. -Deals structured on milestone payments and royaltiesLicensing of Pimecrolimus (anti-inflammatory drug) to Avantec Medical, Biotronics, and Connor MedisystemsIdentified device platforms and suitable drugs for local drug delivery therapy in acute macular edema, solid tumor, ductie carcinomas, osteoarthritic joint disease, and peripheral arterial diseaseCardiovascular CDMA representative to deal evaluation teams for the in-licensing of recombinant elastin, recombinant Relaxin, and ElinogrelParticipated in preclinical and/or clinical development of four registered drugsSpecialties: Internationally recognized expert for identification, licensing, and implementation of drugs/biologics onto medical devices as adjunct and/or vehicles for local delivery in multiple clinical indications.sssumnconsulting@gmail.com